CHST7 Inhibitors

CHST7 inhibitors are chemical entities designed to modulate the sulfation activity mediated by the CHST7 enzyme. One method to inhibit CHST7 is by disrupting the availability of the universal sulfate donor PAPS. Chlorate serves this purpose by interfering with PAPS synthesis, thereby reducing overall sulfation. The use of an inactive PAPS analog can also inhibit CHST7 by competing with the natural substrate, leading to decreased enzymatic activity.

Enzymes like aryl sulfatase can degrade sulfate esters, providing an indirect approach to counteract the effects of CHST7. The introduction of certain compounds known to inhibit sulfotransferases, such as gossypol, quercetin, and phloretin, can also influence CHST7 activity. Other compounds, such as ozagrel and mafenide, may indirectly affect CHST7 by modifying related pathways, such as prostaglandin metabolism or the action of carbonic anhydrase. Compounds like pentosan polysulfate, being heavily sulfated, might directly bind and interfere with the sulfation process. Finally, agents like acetaminophen, in overdose conditions, can deplete sulfate levels, indirectly affecting CHST7 activity. Collectively, these compounds offer a variety of mechanisms that can modulate CHST7 function.